Home

Insights

Caplin Point Laboratories Ltd P/E Ratio

Caplin Point Laboratories Ltd P/E Ratio

download
stocks purchased

₹ 0.3 Cr

Volume transacted

stocks purchased

2.4 K

stocks traded

Image

Caplin Point Laboratories Ltd

NSE: CAPLIPOINT

PE

23.3

Last updated : 20 Jun 07:01 AM

Key Highlights

    The P/E Ratio of Caplin Point Laboratories Ltd is 23.3 as of 20 Jun 07:01 AM .a1#The P/E Ratio of Caplin Point Laboratories Ltd changed from 17.2 on March 2019 to 12 on March 2023 . This represents a CAGR of -6.95% over 5 years. a1#The Latest Trading Price of Caplin Point Laboratories Ltd is ₹ 1415 as of 20 Jun 12:24 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 31.6. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Pharmaceuticals industry is 101.4. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of Caplin Point Laboratories Ltd changed from ₹ 3042 crore on March 2019 to ₹ 4529 crore on March 2023 . This represents a CAGR of 8.28% over 5 years. a1#The Revenue of Caplin Point Laboratories Ltd changed from ₹ 360.27 crore to ₹ 470.57 crore over 8 quarters. This represents a CAGR of 14.29% a1#The EBITDA of Caplin Point Laboratories Ltd changed from ₹ 116.12 crore to ₹ 162.58 crore over 8 quarters. This represents a CAGR of 18.33% a1#The Net Profit of Caplin Point Laboratories Ltd changed from ₹ 86.31 crore to ₹ 121.23 crore over 8 quarters. This represents a CAGR of 18.52% a1#The Dividend Payout of Caplin Point Laboratories Ltd changed from 11.23 % on March 2019 to 14.58 % on March 2023 . This represents a CAGR of 5.36% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1917.2
Mar '209.9
Mar '2112.6
Mar '2217.2
Mar '2312

Fundamental Metrics

Market Cap

10,637 Cr

EPS

60.2

P/E Ratio (TTM) *

23.3

P/B Ratio (TTM) *

4.6

Day’s High

1422.35

Day’s Low

1396.15

DTE *

0.0

ROE *

19.7

52 Week High

1617.8

52 Week Low

781.25

ROCE *

24.3

* All values are consolidated

Last Updated time: 20 Jun 07:01 AM

* All values are consolidated

Last Updated time: 20 Jun 07:01 AM

Image

Caplin Point Laboratories Ltd

NSE: CAPLIPOINT

PRICE

1415.8

15.05 (1.07%)

stock direction

Last updated : 20 Jun 12:24

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Caplin Point Laboratories Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Caplin Point Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value

Market Value

10,638

Asset Value

1,423

6.5 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Company NamePEMarket Cap (INR Cr.)
Sun Pharmaceuticals Industries Ltd36360,896
Cipla Ltd29125,905
Divis Laboratories Ltd74118,864
Zydus Lifesciences Ltd28108,024
Dr Reddys Laboratories Ltd1799,341
Caplin Point Laboratories Ltd2310,637

Key Valuation Metric

Earnings

457 Cr

23.3 X

PE Ratio

Market Cap

₹10637Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

457 Cr

23.3 X

PE Ratio

Market Cap

₹10637Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '193043
Mar '202136
Mar '213057
Mar '225153
Mar '234529

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22360
Sep '22376
Dec '22386
Mar '23401
Jun '23407
Sep '23431
Dec '23453
Mar '24471

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '22116
Sep '22122
Dec '22124
Mar '23135
Jun '23139
Sep '23158
Dec '23159
Mar '24163

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '2286
Sep '2292
Dec '2297
Mar '23101
Jun '23104
Sep '23116
Dec '23120
Mar '24121

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1911
Mar '2010
Mar '2115
Mar '2216
Mar '2315

* All values are a in %

About Caplin Point Laboratories Ltd

About Caplin Point Laboratories Ltd

    Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil). The company came out with a public issue in Nov.'94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord Laboratories, US, for specific products, with a 30% buyback arrangement. It also imports bio-technological products to market them in India. The company has established a trading branch in Nairobi, Kenya, to sell its products in East Africa. It has also established a warehouse in Miami, US, by entering into a marketing tie-up with Lockett Medical Corporation, US.During the year 2015, the Company has invested a sum of Rs 89.10 Lakhs in Argus Salud Pharma LLP. Consequently the Company's share in LLP has increased to 99.90% in Argus Salud Pharma LLP.In October 2016, the Company had subdivided the shares from the face value of Rs 10/- to Rs 2/- and upon sub-division, the members were issued five equity shares of Rs 2/- each in lieu of one equity share of Rs 10/- each. After sub-division, the paid up capital of Rs15,11,00,000 was sub- divided into 7,55,50,000 equity shares of Rs 2/- each.As on 31 March 2018, the Company has three subsidiaries, viz Argus Salud Pharma LLP, Caplin Point Far East Limited - Hongkong and Caplin Point Laboratories Colombia SAS- Colombia. During the year 2019, the Company transferred its regulated markets injectable business which, inter-alia includes US FDA approved injectable plant and Department of Science and Industrial Research (DSIR) recognised R& D Units CP4 and CP 5 to Caplin Steriles Limited, a Wholly Owned Subsidiary Company for which the approval was granted by the members of the Company by way of Special Resolution through Postal Ballot on December 31, 2018. In FY2019, the Company attracted investments in Caplin Steriles Limited from Eight Roads Ventures India Ill LP and F-Prime Capital Partners Life Sciences Fund VI LP in the form of Compulsorily Convertible Preference Shares (CCPS), which shall be converted into equity shares of Caplin Steriles Limited based on the agreed terms. During FY 2019, the Company formed a Joint Venture, Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Hainan Province of China, which will be focusing on international trade of medicines and establishment of marketing team in India and China for export of composite formulations to customers in China, India, Europe and Latin America. In FY'21, Company acquired four channel partners in Latin America, strengthening control on marketing, distribution and supply chain. It launched an e-commerce website named QueTenX', a part of the 10X healthcare portal, transforming credit sales into cash, enhancing an analysis of demand and supply patterns and replenishment stocks through technology tools. It deepened capabilities by stocking essential products at warehouses during the COVID-19 months. It commissioned a DGCI-approved CRO facility and captive API development kilo lab to facilitate backward integration. It received approvals for nine of 18 ANDAs filed (six for Caplin Steriles); five products launched; the next four to be launched in the near future. It embarked on a pipeline of 15 ANDAs to be filed within 24 months with an addressable market size of USD 1.95 billion. It completed ab scale batches for 17 products for US (by Caplin's API division) and trebled capacity of the manufacturing facility. The Company received four ANDA approvals since January 2021, increasing approved ANDAs to 15 (ten under Caplin's name and five through partners). It launched eight products in US; four products are ready for launch and three are likely to be launched before December 2021. It received large tender orders worth $18 million in two markets and has started R&D for API and Oncology formulations in existing and new markets. The registrations for formulations are in progress as such. The design /detailed engineering for Phase 2 of Injectable Plant is complete. Overall Project cost is Rs. 140 Crore and will include 2 Vial lines, one Lyophilizer line, one Pre- filled syringe line and provision to add another Pre-mix bag line. During the year 2022-23, the Company had disposed its entire investment in Caplin Point Laboratories Colombia SAS to Caplin Point Far East Limited - Hong Kong, a wholly - owned subsidiary of the Company and effective from March 28, 2023, Caplin Point Laboratories Colombia SAS ceased to be a subsidiary but became a step-down subsidiary. In 2023, Caplin doubled its capacity to produce Softgel formulation at its Puducherry facility. The Company implemented the latest, S4 hana, version of SAP - enterprise resource planning system. It developed new line of products i.e. Oncology. It completed 4 complex products Exhibit Batches, which includes 3 Injectables and 1 Ophthalmic; launched co-labelled products in the US, for 4 approved products. It launched 23 new products in Central America which has contributed to $2.4m dollars in sale. The second line of production in Softgel dosage was completed in 2023. It acquired an API plant in Visakhapatnam, Andhra Pradesh.

Caplin Point Laboratories Ltd News Hub

News

Caplin Point Laboratories allots 68,550 equity shares under ESOS

Caplin Point Laboratories has allotted 68,550 equity shares under ESOS on 19 June 2024. Po...

Read more

19 Jun 202414:17

News

Caplin Steriles receives USFDA approval for Phenylephrine hydrochloride Ophthalmic solution

Caplin Steriles (Caplin), a subsidiary of Caplin Point Laboratories has been granted final...

Read more

24 May 202412:26

News

Board of Caplin Point Laboratories recommends Interim Dividend

Caplin Point Laboratories announced that the Board of Directors of the Company at its meet...

Read more

16 May 202414:24

News

Caplin Point Laboratories announces board meeting date

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on ...

Read more

10 May 202411:22

News

Caplin Point Laboratories receives INVIMA approval for Softgel Capsules division at Puducherry

Caplin Point Laboratories has received Colombia's INVIMA approval for its Softgel Capsules...

Read more

06 May 202414:53

News

Caplin Steriles receives USFDA approval for Ofloxacin Ophthalmic Solution USP 0.3%

Caplin Steriles, a Subsidiary Company of Caplin Point Laboratories has been granted final ...

Read more

16 Apr 202411:32

Product Composition by Percentage (Revenue)

FAQs for PE of Caplin Point Laboratories Ltd

What is Caplin Point Laboratories Ltd current share price?

The current market price of Caplin Point Laboratories Ltd as of June 20, 2024 is ₹1415.80.

Is Caplin Point Laboratories Ltd a good investment?

As per BlinkX Score Caplin Point Laboratories Ltd scores 18 in Revenue, 33 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Caplin Point Laboratories Ltd's total net assets?

According to Caplin Point Laboratories Ltd's most recent financial filings, the company's net assets total ₹1423.3 Cr.

Is Caplin Point Laboratories Ltd making a profit or loss?

Caplin Point Laboratories Ltd's net Profit as of June 20, 2024 is close to ₹457 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199